BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced today that it will host a Key Opinion Leader event on the topic of dry age-related macular degeneration (AMD) in New York City on Tuesday, July 25. The meeting will feature a presentation by key opinion leader David S. Boyer, MD, Retina-Vitreous Associates, who will discuss the clinical perspective and cell therapy treatment options for patients with dry age-related macular degeneration.

Dr. Boyer is a world-renowned clinician, surgeon and educator. He completed his medical degree at the Chicago Medical School. In 1976, he finished his residency at the U.S.C. County Medical Center. A yearlong retinal surgery fellowship at the Wills Eye Hospital, located in Philadelphia, completed his training. He is currently a leading investigator for various national clinical trials on retinal diseases and serves as an advisor for multiple research, educational and charitable institutions.

BioTime's management team will also provide an overview of the Company's ongoing clinical development work with OpRegen ®, being studied for patients with dry AMD, including recently presented new clinical trial data from this year's Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). OpRegen is now in a Phase I/IIa dose finding study to evaluate its safety and efficacy in patients who have an advanced stage of the disease, and has received fast track designation by the FDA.

The lunch event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance to if you plan to attend in person, as space is limited.

A live webcast of the event, with slides, will be available at and within the Investors section of the Company's website at

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what the company believes to be the world's premier collection of pluripotent cell assets. The foundation of BioTime's core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. and OncoCyte Corporation, which BioTime founded and which, until recently, were majority-owned consolidated subsidiaries of BioTime.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

View source version on

Copyright Business Wire 2010